| Michael Mazza, MD | |
|
1500 East Medical Center Dr, B1 Floor University Hospital Recp C, Ann Arbor, MI 48109-5030 | |
| (734) 936-4566 | |
| Not Available |
| Full Name | Michael Mazza |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 25 Years |
| Location | 1500 East Medical Center Dr, Ann Arbor, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639250764 | NPI | - | NPPES |
| 4630889 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 4301083878 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Michigan Health System | Ann arbor, MI | Hospital |
| Metro Health Hospital | Wyoming, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Metropolitan Hospital | 5597651836 | 352 |
| Regents Of The University Of Michigan | 3779496856 | 2953 |
News Archive
Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today compelling final data from a Phase II study of the Company's proprietary opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED).
When hospitalists use discharge communication software, patients and the outpatient doctors who carry out the care have better perceptions of the quality of the discharge process, according to new research published in the August issue of the Journal of Hospital Medicine.
In a study of men with an average age of 71 years, lifestyle factors such as never smoking, maintaining a healthy diet, and not being obese were associated with survival and high functionality over the next 16 years.
LTW Technologies has received 5 FDA clearances (K082586) for its proprietary and unique multi-wavelength LED LIGHTWAVE therapy device. The LIGHTWAVE DELUXE series utilizes a revolutionary light therapy combination of Red light therapy, Blue light therapy and Infrared light therapy.
› Verified 1 days ago
| Entity Name | Regents Of The University Of Michigan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205868353 PECOS PAC ID: 3779496856 Enrollment ID: O20031106000325 |
News Archive
Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today compelling final data from a Phase II study of the Company's proprietary opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED).
When hospitalists use discharge communication software, patients and the outpatient doctors who carry out the care have better perceptions of the quality of the discharge process, according to new research published in the August issue of the Journal of Hospital Medicine.
In a study of men with an average age of 71 years, lifestyle factors such as never smoking, maintaining a healthy diet, and not being obese were associated with survival and high functionality over the next 16 years.
LTW Technologies has received 5 FDA clearances (K082586) for its proprietary and unique multi-wavelength LED LIGHTWAVE therapy device. The LIGHTWAVE DELUXE series utilizes a revolutionary light therapy combination of Red light therapy, Blue light therapy and Infrared light therapy.
› Verified 1 days ago
| Entity Name | Metropolitan Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811937519 PECOS PAC ID: 5597651836 Enrollment ID: O20040507000012 |
News Archive
Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today compelling final data from a Phase II study of the Company's proprietary opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED).
When hospitalists use discharge communication software, patients and the outpatient doctors who carry out the care have better perceptions of the quality of the discharge process, according to new research published in the August issue of the Journal of Hospital Medicine.
In a study of men with an average age of 71 years, lifestyle factors such as never smoking, maintaining a healthy diet, and not being obese were associated with survival and high functionality over the next 16 years.
LTW Technologies has received 5 FDA clearances (K082586) for its proprietary and unique multi-wavelength LED LIGHTWAVE therapy device. The LIGHTWAVE DELUXE series utilizes a revolutionary light therapy combination of Red light therapy, Blue light therapy and Infrared light therapy.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Mazza, MD 3621 S State St, 700 Kms Place, Ann Arbor, MI 48108 Ph: (734) 936-2047 | Michael Mazza, MD 1500 East Medical Center Dr, B1 Floor University Hospital Recp C, Ann Arbor, MI 48109-5030 Ph: (734) 936-4566 |
News Archive
Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today compelling final data from a Phase II study of the Company's proprietary opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED).
When hospitalists use discharge communication software, patients and the outpatient doctors who carry out the care have better perceptions of the quality of the discharge process, according to new research published in the August issue of the Journal of Hospital Medicine.
In a study of men with an average age of 71 years, lifestyle factors such as never smoking, maintaining a healthy diet, and not being obese were associated with survival and high functionality over the next 16 years.
LTW Technologies has received 5 FDA clearances (K082586) for its proprietary and unique multi-wavelength LED LIGHTWAVE therapy device. The LIGHTWAVE DELUXE series utilizes a revolutionary light therapy combination of Red light therapy, Blue light therapy and Infrared light therapy.
› Verified 1 days ago
Chiemezie Chianotu Amadi, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Patrick Charles Albus, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Dr. Michael James Todd, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Perry G Pernicano, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1500 East Medical Center Dr, B1 Floor University Hospital Recp C, Ann Arbor, MI 48109 Phone: 734-936-4566 | |
Ellen G Hoeffner, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1500 East Medical Center Dr, B1 Floor University Hospital Recp C, Ann Arbor, MI 48109 Phone: 734-936-4566 | |
Dr. Christopher Robert Nall, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1500 E Medical Center Dr, Ann Arbor, MI 48109 Phone: 734-936-4000 | |
Dr. Stephen Michael Ascherl, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 2375 Newport Rd, Ann Arbor, MI 48103 Phone: 734-327-0649 Fax: 734-327-0649 |